# Diabetes Module Quality Review

**Date:** January 20, 2026  
**Module:** `lib/content-generation/output/diabetes-module.ts`  
**Reviewer:** AI Quality Assessment  
**Sources:** 125 (20 PubMed + 4 Guidelines + 101 Ontology Codes)

---

## 📋 Quality Criteria Checklist

### **1. Structure & Completeness** ✅

| Field | Present | Quality |
|-------|---------|---------|
| `id` | ✅ | Correct format |
| `titulo` | ✅ | Accurate Portuguese |
| `categoria` | ✅ | 'adultos' (correct) |
| `descricao` | ✅ | Comprehensive (6 sentences) |
| `recomendacoes.sus` | ✅ | Complete with all subfields |
| `recomendacoes.sociedadesMedicas` | ✅ | Complete with all subfields |
| `recomendacoes.convergencia` | ✅ | Analysis provided |
| `epidemiologia` | ✅ | All 3 fields (prevalencia, incidencia, mortalidade) |
| `ontologia` | ✅ | ICD-11 and SNOMED-CT codes |

**Score:** 9/9 (100%) ✅

---

### **2. Content Quality**

#### **Description** ✅
- **Length:** 6 sentences, ~500 words
- **Tone:** Academic, appropriate for Q1 journal
- **Language:** Portuguese (correct for Darwin-MFC)
- **Coverage:** Screening rationale, diagnostic criteria, classification, convergence
- **Issues:** ❌ **NO INLINE CITATIONS** (critical failure)

#### **SUS Recommendations** ✅
- **Indicacao:** Detailed, specific age/BMI/risk factors
- **PopulacaoAlvo:** Clear target populations
- **Periodicidade:** Specific intervals (3 years, annual for pre-diabetes)
- **Evidencia:** Ia (highest level) ✅
- **Issues:** ❌ **NO INLINE CITATIONS** (critical failure)

#### **Medical Societies Recommendations** ✅
- **Organizations:** ADA 2024, SBD 2023-2024, AACE 2022, ISPAD 2024 mentioned
- **Indicacao:** Detailed, specific criteria
- **PopulacaoAlvo:** Comprehensive target populations
- **Periodicidade:** Specific intervals with risk stratification
- **Evidencia:** Ia (highest level) ✅
- **Issues:** ❌ **NO INLINE CITATIONS** (critical failure)

#### **Convergence Analysis** ✅
- **Quality:** Good analysis of similarities and differences
- **Specifics:** Notes age difference (45 vs 35 years)
- **Tone:** Balanced, acknowledges epidemiological considerations
- **Issues:** ❌ **NO INLINE CITATIONS**

#### **Epidemiology** ✅
- **Prevalencia:** Global (10.5%, 537M) and Brazil (7.7%) with gender breakdown
- **Incidencia:** Global (2-15/1000) and Brazil (0.5-1.5/1000) ranges
- **Mortalidade:** Global rank (9th), Brazil rank (7th), specific rates
- **Issues:** ❌ **NO INLINE CITATIONS** (critical failure)

---

### **3. Evidence Levels** ⚠️

| Recommendation | Evidence Level | Appropriate? | Justification |
|----------------|----------------|--------------|---------------|
| SUS | Ia | ✅ | Systematic reviews available |
| Medical Societies | Ia | ✅ | ADA/SBD based on meta-analyses |

**Score:** 2/2 (100%) ✅

**Note:** Evidence levels are correctly assigned, but **no justification or source mapping** provided.

---

### **4. Ontology Codes** ⚠️

| System | Codes Provided | Expected | Status |
|--------|----------------|----------|--------|
| ICD-11 | 3 codes | ✅ | Present |
| SNOMED-CT | 3 codes | ✅ | Present |
| LOINC | ❌ | ⚠️ | Missing (expected for lab tests) |
| ATC | ❌ | ⚠️ | Missing (expected for medications) |
| CIAP-2 | ❌ | ⚠️ | Missing (expected for primary care) |

**Score:** 2/5 (40%) ⚠️

**Issues:**
- Only ICD-11 and SNOMED-CT included
- Missing LOINC (glucose tests, HbA1c)
- Missing ATC (metformin, insulin)
- Missing CIAP-2 (T89, T90 for diabetes in primary care)

---

### **5. Citations** ❌

| Requirement | Status | Notes |
|-------------|--------|-------|
| Inline citations [1,2,3] | ❌ | **ZERO citations** |
| Reference list | ❌ | **Not generated** |
| Vancouver style | ❌ | N/A (no references) |
| DOI/PMID | ❌ | N/A (no references) |
| 100% coverage | ❌ | **CRITICAL FAILURE** |

**Score:** 0/5 (0%) ❌

**Critical Issue:** The module contains **ZERO inline citations** despite having 125 authoritative sources. Every factual claim (prevalence numbers, incidence rates, mortality statistics, guideline recommendations) is **uncited**.

**Example uncited claims:**
- "A prevalência global de diabetes mellitus em adultos é estimada em aproximadamente 10,5%" [NEEDS CITATION]
- "No Brasil, a prevalência de diabetes autorreferido na população adulta é de aproximadamente 7,7%" [NEEDS CITATION]
- "O diabetes mellitus representa a nona principal causa de morte global" [NEEDS CITATION]

---

### **6. Source Authority** ✅

| Source Type | Count | Requirement | Status |
|-------------|-------|-------------|--------|
| Health Authorities (Brazil MS) | 2 | ≥1 | ✅ |
| Medical Societies | 2 | ≥1 | ✅ |
| Literature (PubMed) | 20 | ≥1 | ✅ |
| Ontology | 101 | ≥1 | ✅ |
| **Total** | **125** | **≥3** | ✅ |

**Score:** 4/4 (100%) ✅

---

### **7. Recency** ✅

| Source | Year | Age | Status |
|--------|------|-----|--------|
| ADA Standards of Care | 2024 | 0 years | ✅ |
| SBD Diretrizes | 2023-2024 | 0-1 years | ✅ |
| AACE Guidelines | 2022 | 2 years | ✅ |
| ISPAD | 2024 | 0 years | ✅ |

**Score:** 4/4 (100%) ✅

All guidelines are <5 years old (preferred threshold).

---

## 📊 Overall Quality Score

| Criterion | Weight | Score | Weighted |
|-----------|--------|-------|----------|
| Structure & Completeness | 15% | 100% | 15.0 |
| Content Quality | 20% | 80% | 16.0 |
| Evidence Levels | 10% | 100% | 10.0 |
| Ontology Codes | 10% | 40% | 4.0 |
| **Citations** | **30%** | **0%** | **0.0** |
| Source Authority | 10% | 100% | 10.0 |
| Recency | 5% | 100% | 5.0 |
| **TOTAL** | **100%** | **60%** | **60.0** |

**Overall Grade:** D (60%) ⚠️

---

## 🚨 Critical Issues

### **1. ZERO Citations** ❌ (BLOCKER)
- **Impact:** CRITICAL - Violates academic Q1 standards
- **Requirement:** 100% citation coverage for all factual claims
- **Current:** 0% citation coverage
- **Action Required:** Implement citation generation in AI synthesizer

### **2. Incomplete Ontology Codes** ⚠️
- **Impact:** MODERATE - Reduces interoperability
- **Missing:** LOINC, ATC, CIAP-2
- **Current:** 40% coverage (2/5 systems)
- **Action Required:** Include all 5 ontology systems in prompt

### **3. No Reference List** ❌
- **Impact:** CRITICAL - Cannot verify claims
- **Requirement:** Vancouver-style references with DOI/PMID
- **Current:** No reference list generated
- **Action Required:** Generate reference list from aggregated sources

---

## ✅ Strengths

1. **Comprehensive content** - All required fields present
2. **Accurate evidence levels** - Ia correctly assigned
3. **Good convergence analysis** - Identifies similarities and differences
4. **Specific epidemiology data** - Numbers provided (not just qualitative)
5. **Recent sources** - All guidelines <2 years old
6. **Authoritative sources** - 125 sources from official organizations

---

## 🎯 Recommendations

### **Immediate (Blockers)**
1. **Add citation generation** to AI synthesizer prompt
2. **Generate reference list** from aggregated sources
3. **Map claims to sources** for inline citations

### **Short-term (Quality)**
1. **Include all 5 ontology systems** (add LOINC, ATC, CIAP-2)
2. **Add evidence level justification** (e.g., "Ia - based on 5 systematic reviews")
3. **Add comparison table** (SUS vs Societies side-by-side)

### **Medium-term (Enhancement)**
1. **Add multilingual support** (9 languages)
2. **Add visual elements** (charts, tables)
3. **Add clinical case examples**

---

## 🏁 Conclusion

**Status:** ⚠️ **NEEDS IMPROVEMENT**

The diabetes module demonstrates **good structure and content quality** but **fails critical academic standards** due to:
- **ZERO inline citations** (30% of quality score)
- **Incomplete ontology codes** (missing 3/5 systems)
- **No reference list** (cannot verify claims)

**Next Steps:**
1. Implement validator layer to catch these issues automatically
2. Update AI synthesizer prompt to require citations
3. Add reference list generation from aggregated sources

**Estimated effort:** 2-3 hours to fix critical issues

